Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Abstract: Nowadays, as the demand for accurate object detection (OD) applications is increasing, several attempts have been made to introduce convolutional neural network (CNN)-based super-resolution ...

Abstract: Current adversarial attacks pose a serious threat to the robustness of visual-language models (VLMs), including vision-language pre-trained models (VLPMs) and multimodal large language ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Breakthroughs, discoveries, and DIY tips sent every weekday. Terms of Service and Privacy Policy. If you close one eye or put a finger to your ear, there’s an ...

With the open-source Dataverse SDK for Python (announced in Public Preview at Microsoft Ignite 2025), you can fully harness the power of Dataverse business data. This toolkit enables advanced ...

If only they were robotic! Instead, chatbots have developed a distinctive — and grating — voice. Credit...Illustration by Giacomo Gambineri Supported by By Sam Kriss In the quiet hum of our digital ...